← Back to catalogue

Tibial Insert Trial, PS-Max, Klassic ONE

FDA UDI

Class I (US FDA UDI)

by Total Joint Orthopedics, Inc.

Identity

Trade Name
Tibial Insert Trial, PS-Max, Klassic ONE FDA UDI
Generic Name
Knee tibia prosthesis trial, reusable FDA UDI
Device Name
Tibial Insert Trial, PS-Max, Klassic ONE Size 1, 21mm FDA UDI
Model / Reference
2252.01.021 FDA UDI
Description
Tibial Insert Trial, PS-Max, Klassic ONE Size 1, 21mm FDA UDI

Identifiers

Primary DI / UDI-DI
00819251028639 FDA UDI
FDA Product Code
LXH FDA UDI
GMDN Term
Knee tibia prosthesis trial, reusable FDA UDI

Classification

Device Class
Class I FDA UDI
Regulation Number
888.4540 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

No

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

No

FDA UDI

Manufacturing Date

No

FDA UDI
Sterilization Method
Moist Heat or Steam Sterilization FDA UDI

Category: Knee tibia prosthesis trial, reusable

The Tibial Insert Trial, PS-Max, Klassic ONE is a reusable knee tibia prosthesis trial designed for unicompartmental knee replacement surgery or total knee arthroplasty (TKA) to determine the correct alignment, size, and fit of the final prosthesis. This graduated-size trial includes features such as tibial base plate trials, tibial spacer trials, tibial insert trials, and guide pin trials, all made of metal or polymer material.

Similar devices

Also classified as Knee tibia prosthesis trial, reusable.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI bc98507f-fb19-4a0c-bfa1-7376b90ce08b 36 fields · synced Jul 21, 2026